摘要目前,诸多以免疫清除脑内β-淀粉样蛋白(Aβ)斑块为标靶的阿尔茨海默病(AD)免疫治疗研究因均未达到预期的临床效果而陷入空前的困境.近年来研究表明,低密度脂蛋白受体相关蛋白1(LRP1)可通过多种途径参与Aβ的生成及非免疫清除,从而显示出一种异于经典Aβ免疫治疗的干预靶点潜质.为此,笔者现重点阐述LRP1在生理及AD状态下Aβ代谢过程中的作用,并展望其作为一种全新干预靶点在未来AD防治中的应用前景.

abstractsAlmost all active immunotherapy attempts which targeted at clearing or reducing β-amyloid (Aβ) plaques in brains of patients with Alzheimer'disease (AD) were fallen into unprecedented difficulties,because of unsatisfactory curative effects.Recently,more and more evidences support that low density lipoprotein receptor related protein 1 (LRP1) is involved in Aβ production and clearance through multiple non-immune pathways,which has showed the potential as a whole-new interference target different with classical Aβ immunotherapies.So,we try to summarize the research developments of roles of LRP1 in Aβ metabolic process in physiological and AD conditions,and look forward to its possible applications in the prevention and treatment of AD.